In a filing, Ligand Pharmaceuticals, Inc revealed its Director LAMATTINA JOHN L unloaded Company’s shares for reported $0.3 million on Nov 27 ’24. In the deal valued at $123.65 per share,2,406 shares were sold. As a result of this transaction, LAMATTINA JOHN L now holds 29,515 shares worth roughly $3.38 million.
Then, LAMATTINA JOHN L bought 2,406 shares, generating $286,771 in total proceeds.
Before that, Korenberg Matthew E bought 32,183 shares. Ligand Pharmaceuticals, Inc shares valued at $3,872,684 were divested by the Officer at a price of $120.33 per share.
Oppenheimer initiated its Ligand Pharmaceuticals, Inc [LGND] rating to an Outperform in a research note published on October 03, 2024; the price target was $135. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. H.C. Wainwright maintained its rating on February 04, 2021. It rated LGND as “a Buy”.
Price Performance Review of LGND
On Friday, Ligand Pharmaceuticals, Inc [NASDAQ:LGND] saw its stock jump 0.61% to $114.64. Over the last five days, the stock has lost -1.94%. Ligand Pharmaceuticals, Inc shares have risen nearly 60.52% since the year began. Nevertheless, the stocks have risen 65.35% over the past one year. While a 52-week high of $129.90 was reached on 11/07/24, a 52-week low of $67.53 was recorded on 01/17/24. SMA at 50 days reached $115.07, while 200 days put it at $95.52.
Levels Of Support And Resistance For LGND Stock
The 24-hour chart illustrates a support level at 111.94, which if violated will result in even more drops to 109.23. On the upside, there is a resistance level at 116.41. A further resistance level may holdings at 118.17. The Relative Strength Index (RSI) on the 14-day chart is 46.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.41%. Stochastics %K at 12.83% indicates the stock is a buying.
How much short interest is there in Ligand Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Ligand Pharmaceuticals, Inc stocks on 2024-11-29, dropping by -0.13 million shares to a total of 0.79 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 0.92 million shares. There was a decline of -16.92%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 06, 2020 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $156 price target.
